Pursuing IRF4 as a therapeutic opportunity for lymphoid malignancies

The molecule IRF4 is essential to the function of the immune system. In this application we investigate mouse models with mutations in IRF4 that are identical to those found in patients with cancers of the immune system. We will investigate how these mutations affect binding of IRF4 to the DNA and how changes in the IRF4-DNA binding domain lead to formation of tumours and how this interaction can be targeted therapeutically.